Physician profile
Collin Beckstrom
NPI 1558999482
$3,101.81
in general payments reported to CMS, 2019-2025
17 companies · $1,563 in 2025
The $1,563 reported for 2025 was more than what 92% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $19.93 · 2023: $799 · 2024: $719 · 2025: $1,563.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,032 · Education: $49.92.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,031.96 |
| Education | $49.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,839.53 | 2023-2025 | Skyrizi, Rinvoq |
| Janssen Scientific Affairs, LLC | $300.67 | 2024-2025 | Tremfya, Stelara |
| Apollo Endosurgery US INC | $155.56 | 2023 | Overstitch Endoscopic Suturing System |
| Janssen Biotech, INC. | $146.24 | 2025 | Tremfya |
| Ipsen Biopharmaceuticals, INC | $102.44 | 2024 | Iqirvo |
| Gilead Sciences, INC. | $98.46 | 2025 | Epclusa |
| Novo Nordisk INC | $91.66 | 2025 | Wegovy |
| Mallinckrodt Hospital Products INC. | $91.47 | 2025 | Terlivaz |
| Boston Scientific Corporation | $55.07 | 2025 | Captivator II, Overstitch Endoscopic Suturing System |
| Celltrion USA INC. | $49.92 | 2024 | Zymfentra |
| Intercept Pharmaceuticals, INC. | $35.92 | 2025 | |
| Madrigal Pharmaceuticals | $34.07 | 2025 | Rezdiffra |
| Pfizer INC. | $28.22 | 2024-2025 | |
| Eton Pharmaceuticals, INC. | $23.94 | 2025 | Betaine Anhydrous, Nitisinone, Carglumic Acid |
| Tanabe Pharma America, INC. | $19.93 | 2021 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.50 | 2023 | Xifaxan |
| Regeneron Healthcare Solutions, INC. | $14.21 | 2025 | Dupixent |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Collin Beckstrom listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.